tbuckley/cabot-search huggingface dataset:
Prognosis after heart transplantation
Authors: A. Anyanwu
Journal: BMJ (2003)

Heart transplantation is in its third decade as a widely accepted treatment for advanced heart failure. What is its prognosis? In the early era of heart transplantation, the perceived alternative to transplantation was imminent death. In 1968, at the beginning of heart transplantation, Peter Medawar, the eminent zoologist and Nobel laureate whose work on tolerance set the scene for successful transplantation, correctly predicted: “The transplantation of human organs will be assimilated into ordinary clinical practice … and there is no need to be philosophical about it. This will come about for the single and sufficient reason that people are so constituted that they would rather be alive than dead.”1

Heart transplantation has a high early mortality—15-20% of recipients die within a year of the operation. 2 3 Thereafter the death rate is constant, at about 4% a year for the next 18 years, so that 50% of patients can expect to be alive after 10 years and 15% after 20 years. Application of heart transplantation has been based almost entirely on doctors' …
Abstract 12971: Aspirin Use is Not Associated With Primary Prevention of All-Cause, Cardiovascular, or Oncologic Mortality
Authors: Bethany Doran, Yu Guo, Jinfeng Xu, Sripal Bangalore
Journal: Circulation (2014)

Introduction: The role of aspirin in the primary prevention of cardiovascular (CV) disease is controversial, with the FDA recently rejecting a request to market aspirin for primary prevention of heart disease citing too little data showing clear benefit. Few studies have found mortality benefit for using aspirin in primary prevention of CV disease, with some studies showing potential for harm as well. Studies have also suggested that aspirin use may reduce oncologic mortality. Hypothesis: We tested the hypothesis that aspirin use is significantly associated with all-cause, CV, and oncologic mortality. Methods: Using the National Health and Nutrition Examination Survey (NHANES III), we examined the association of aspirin use and all-cause, CV, and oncologic mortality within 15,968 individuals. After weighting, we used propensity score matching within participants using an optimal 1:4 matching technique to control for age, low density lipoprotein cholesterol, glomerular filtration rate, race, gender, use of...
Manchester asthma and allergy study*1Polymorphisms in ADAM33 predict lung function at age 5 years
Authors: A. Simpson, F. Jury, J. Cakebread, L. Lowe, S. Holgate, A. Woodcock, W. Ollier, A. Custovic, J. Holloway, S. John
Journal: Journal of Allergy and Clinical Immunology (2004)
Recurrent Right-Sided Ptosis in a Child
Authors: Partha S. Ghosh
Journal: JAMA Pediatrics (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
TORULA MENINGO-ENCEPHALITIS; A CASE REPORT
Authors: J. Homer Cudmore, James R. Lisa
Journal: Annals of Internal Medicine (1938)

Case Reports1 March 1938TORULA MENINGO-ENCEPHALITIS; A CASE REPORTJ. HOMER CUDMORE, M.D., F.A.C.P., JAMES R. LISA, M.D., F.A.C.P.J. HOMER CUDMORE, M.D., F.A.C.P.Search for more papers by this author, JAMES R. LISA, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-11-9-1747 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSince the contribution of Freeman1 on torula infection of the central nervous system, increasing attention has been paid to this interesting condition. Recently Levine2 has again reviewed the literature, adding 17 more cases, including two of his own, bringing the total number to 60. The present case is reported, not so much because of the rarity of the condition, but to add a new and as yet unreported manifestation of the infection, a cicatrizing lesion of the brain.CASE REPORTThe patient, a white male 30 years old, was admitted to City Hospital on March 15, 1935, complaining of severe...Bibliography1. FREEMAN W: Infection of the central nervous system with torula, Jr. f. Psych. u. Neur., 1931, xliii, 236; abstr. Arch. Neur. and Psych., 1933, xxix, 878. Google Scholar2. LEVINE EA: Torula infection of the central nervous system, Arch. Int. Med., 1937, lix, 667. CrossrefGoogle Scholar3. WEIDMAN F: In discussion of case of Wile.4 Google Scholar4. WILE U: Cutaneous torulosis, Arch. Dermat. and Syph., 1935, xxxi, 58. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication July 23, 1937.From the First Medical Service and the Pathological Laboratory, City Hospital, Welfare Island, Dept. Hospitals, New York, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDie psychischen Störungen bei InfektionskrankheitenCryptococcosisDie psychischen Störungen bei Infektions- und TropenkrankheitenPilzerkrankungenTORULOSIS OF THE CENTRAL NERVOUS SYSTEM: REVIEW OF LITERATURE AND REPORT OF FIVE CASES*WILLIAM H. MOSBERG JR., M.D., JAMES G. ARNOLD JR., M.D.Blastomykose bei LymphogranulomatoseTorulosis of the Central Nervous System 1 March 1938Volume 11, Issue 9Page: 1747-1752KeywordsBrainCentral nervous systemLesionsMedical servicesResearch laboratories ePublished: 1 December 2008 Issue Published: 1 March 1938 PDF downloadLoading ...
Abstract #9: Cyclooxygenase-2 expression in adult SD rat mammary gland reveals roles in hormone stimulation and involution
Authors: Jaime Fornetti, Jenean O'Brien, Katherine Patricia Bell, Pepper Schedin
Journal: Cancer Research (2009)

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

The role of cyclooxygenase-2 (COX-2) in breast cancer is controversial. While some studies indicate that there is an association between COX-2 expression, tumor status, and cancer prognosis, others have failed to detect a relationship between COX-2 and breast cancer. In addition, there is also disagreement regarding the utility of COX inhibitors as anti-cancer agents in breast cancer. Meta-analyses and case control studies have identified a potential reduction in breast cancer risk in women taking non-steroidal anti-inflammatory drugs (NSAIDs), which non-selectively inhibit the cyclooxygenase enzymes. Prospective studies, however, have failed to support such a decrease in risk. To date, the data indicate that COX-2 may play a role in early stage disease rather than cancer progression. Surprisingly, the role of COX-2 in normal mammary gland biology is poorly understood. The goal of the present study was to examine the expression pattern of COX-2 in adult rats with different reproductive states, in order to gain insight into the potential role of COX-2 in breast cancer. Immunohistochemical (IHC) analysis for COX-2 expression in Sprague-Dawley rat mammary glands was performed using tissue from virgin, pregnant, lactating, actively involuting, and fully regressed glands. In addition, rats were stimulated with estrogen plus progesterone or estrogen alone to see if COX-2 is downstream of hormone stimulation in the mammary gland. By IHC, COX-2 was expressed in mammary epithelial cells at all stages of development, but was highest during pregnancy, as well as following treatment with estrogen plus progesterone and estrogen alone, indicating that COX-2 may be downstream of estrogen stimulation. The pattern of COX-2 expression also differed with reproductive state. In the pregnant gland, mammary epithelial cell COX-2 staining was cytoplasmic and diffuse, while in the lactating gland COX-2 appeared to be secreted into the lumen. During weaning-induced involution, the mammary epithelial staining patterned was vesicular, and appeared to co-localize with phagocyte epithelial cells. Strong COX-2 expression was also observed in a sub-set of immune cells. Based on these data, COX-2 functions in both the epithelial and stromal compartments of the normal gland. In mammary epithelium, COX-2 is upregulated during the process of alveolar proliferation experienced during pregnancy and with exogenous estrogen stimulation. Further, COX-2 may play a different role in the gland during lactation and involution. Given the complexity of COX-2 expression in the normal mammary gland, it is likely that the role of COX-2 in breast cancer initiation and progression may be stage and possibly breast cancer sub-type specific.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 9.
Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up.
Authors: Jeffrey Howard Lipton, Timothy P. Hughes, Brian Leber, Carmino De Souza, Pedro E Dorlhiac-Llacer, Juan Luis Steegmann, Agnes Guerci-Bresler, Anthony P. Schwarer, Francisco Cervantes, John Reynolds, LaTonya R Collins, Tomasz K. Szczudlo, Nelson Spector
Journal: Journal of Clinical Oncology (2012)

6505^ Background: Nilotinib induced significantly faster and deeper molecular responses vs imatinib in the ENESTnd trial. Achieving these deeper molecular responses may increase patient eligibility for future TKI discontinuation studies. Methods: CML-CP pts (N = 207) who achieved a complete cytogenetic response but were still BCR-ABL positive by RQ-PCR after ≥ 24 mo on imatinib were randomized 1:1 to receive nilotinib 400 mg BID (n = 104) or to continue their imatinib dose (400 or 600 mg QD [n = 103]). The primary endpoint was confirmed CMR (undetectable BCR-ABL by RQ-PCR with a sample sensitivity of ≥ 4.5 logs in 2 consecutive samples). Other endpoints included molecular responses (MMR ≤ 0.1% IS , MR 4 ≤ 0.01% IS , and MR 4.5 ≤ 0.0032% IS ) and BCR-ABL ratio over time. Results: Rate of confirmed CMR was higher in the nilotinib arm vs imatinib by 12 mo (12.5% vs 5.8%) (Table). Rate of CMR (undetectable BCR-ABL in at least 1 sample) by 12 mo was significantly higher on nilotinib vs imatinib (23.1% vs 10.7%; P = .02). Rates of MMR, MR 4 , MR 4.5 , and CMR were also superior in pts switched to nilotinib, and these pts had significantly shorter times to achieve these responses. Imatinib-treated pts had minimal evidence of improvement in molecular response vs a median 0.5-log reduction in BCR-ABL by 12 mo for the nilotinib cohort. With 12-mo follow-up, 84% of pts remained on nilotinib and 96% on imatinib. The nilotinib safety profile was consistent with prior studies. Both drugs were well tolerated. Conclusions: Twice as many pts achieved deeper molecular responses after switching to nilotinib vs staying on imatinib. [Table: see text]
Abstract 13616: Aorta Atheroma Burden Predicts Acute Cerebrovascular Events after Transcatheter Aortic Valve Implantation: Insights from Volumetric Multislice Computed Tomography Analysis
Authors: Yu Kataoka, Rishi Puri, Anthony D Pisaniello, Mathew I Worthley, Joseph Montarello, Stephen J Nicholls, Stephen G Worthley
Journal: Circulation (2014)

Backgrounds: Cerebrovascular accidents (CVAs) are a major complication of transcatheter aortic valve implantation (TAVI). Proposed mechanisms include atheroembolization of debris during balloon aortic valvuloplasty, deployment of the device or catheter passage through the aorta. The relationship between aortic atheroma burden and acute CVAs after TAVI has not been established. Methods: Preoperative multislice computed tomographic (MSCT) images in 218 patients treated with TAVI were analyzed. Vessel and lumen areas in each 1-mm cross-sectional image from ascending to abdominal aorta were measured. Total atheroma volume (TAV) was calculated and compared in patients with (n=18) and without (n=200) acute CVAs. Results: Patients with acute CVAs were more likely to have a history of cerebrovascular disease (61 v. 14%, p&lt;0.01). MSCT analysis demonstrated that patients having acute CVAs exhibited greater TAV in the ascending aorta (11.9 ± 2.4 v. 9.7 ± 2.0 cm3, p=0.02) and arch (3.1 ± 1.1 v. 2.5 ± 0.5 cm3, p=0.02) but not in the descending (p=0.93) and abdominal aorta (p=0.77). Aortic valve calcification volume did not predict CVAs. TAV in the ascending (p=0.03) and arch (p=0.02), as well as a history of cerebrovascular disease (p=0.03), were independent predictors for acute CVAs after TAVI on multivariate analysis. Receiver-operating characteristic curve analysis identified TAV in the ascending aorta &gt;10.2 cm3 and in the arch &gt;2.8 cm3 as the optimal cutoff for predicting acute CVAs. The incidence of acute CVA was highest (66%) if patients had a history of cerebrovascular disease and TAV in the ascending aorta and arch above these cutoff values (Figure). Conclusions: Patients with acute CVAs after TAVI harbored greater atheroma burden in the ascending aorta and aortic arch. Our finding might underscore preoperative MSCT analysis of aorta atheroma burden to identify high-risk patients for acute CVAs, who may benefit from embolic protection devices during TAVI procedure.
Prescribing Sterile Needles Is Not Only Beneficial but (Mostly) Legal
Authors: C Marwick
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Christ and the Woman Taken in Adultery
Authors: M. Therese Southgate
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association Between the Chromosome 9p21 Locus and Angiographic Coronary Artery Disease Burden
Authors: Kenneth Chan, Riyaz S. Patel, Paul Newcombe, Christopher P. Nelson, Atif Qasim, Stephen E. Epstein, Susan Burnett, Viola L. Vaccarino, A. Maziar Zafari, Svati H. Shah, Jeffrey L. Anderson, John F. Carlquist, Jaana Hartiala, Hooman Allayee, Kunihiko Hinohara, Bok-Soo Lee, Anna Erl, Katrina L. Ellis, Anuj Goel, Arne S. Schaefer, Nour Eddine El Mokhtari, Benjamin A. Goldstein, Mark A. Hlatky, Alan S. Go, Gong-Qing Shen, Yan Gong, Carl Pepine, Ross C. Laxton, John C. Whittaker, W.H. Wilson Tang, Julie A. Johnson, Qing K. Wang, Themistocles L. Assimes, Ute Nöthlings, Martin Farrall, Hugh Watkins, A. Mark Richards, Vicky A. Cameron, Axel Muendlein, Heinz Drexel, Werner Koch, Jeong Euy Park, Akinori Kimura, Wei-feng Shen, Iain A. Simpson, Stanley L. Hazen, Benjamin D. Horne, Elizabeth R. Hauser, Arshed A. Quyyumi, Muredach P. Reilly, Nilesh J. Samani, Shu Ye
Journal: Journal of the American College of Cardiology (2013)
Risk factors for actinic keratosis in eight European centres: a case-control study
Authors: A. Traianou, M. Ulrich, Z. Apalla, E. De Vries, K. Bakirtzi, D. Kalabalikis, L. Ferrandiz, A. Ruiz-de-Casas, D. Moreno-Ramirez, D. Sotiriadis, D. Ioannides, S. Aquilina, C. Apap, R. Micallef, L. Scerri, S. Pitkänen, O. Saksela, E. Altsitsiadis, B. Hinrichs, C. Magnoni, C. Fiorentini, S. Majewski, A. Ranki, C.M. Proby, E. Stockfleth, M. Trakatelli
Journal: British Journal of Dermatology (2012)

Background There are limited data regarding the association of actinic keratosis (AK) and other types of nonmelanoma skin cancer (NMSC); studies investigating possible correlation of AK with melanocytic naevi are even scarcer. To our knowledge, there are no data examining the risk of AK in people using specific medications. Objective To investigate constitutional and exposure risk factors leading to AK and the coexistence of AK with NMSC and melanoma. Methods A multicentre hospital‐based case–control study was performed in Finland, Germany, Greece, Italy, Malta, Poland, Scotland and Spain, including 343 patients with actinic keratosis (AK), 409 with squamous cell carcinoma (SCC), 602 with basal cell carcinoma (BCC), 360 with invasive melanoma and 119 with in situ melanoma, and 686 control subjects. Exposures were assessed by questionnaires that were partly self‐administered and partly filled out by dermatologists. Unconditional logistic regression modelling was used to assess associations including the influence of phenotypic characteristics, presence of naevi, sun‐exposure habits and certain drugs on AK risk. Results Differences in hair and eye coloration variably influenced the risk for AK, with red hair signifying a seven times higher risk [odds ratio (OR) 6·9, 95% confidence interval (CI) 4·34–11·00), and brown – compared with blue – eyes, about a 40% reduced risk (OR 0·61, 95% CI 0·13–0·92). The darker the skin phototype, the lower the risk for AK, with phototype IV exhibiting nine times less risk of developing AK. Some and many freckles on the arms were associated with an OR of 1·8 (95% CI 1·08–2·81) and 3·0 (95% CI 1·10–3·54), respectively, while overall number of naevi and high educational level were inversely associated with AK. Sun exposure, thiazide diuretics and cardiac drugs had a higher risk for AK. SCC was the most frequent (58%) skin neoplasm coexisting with AKs, followed by BCC (30%), melanoma in situ (12%) and invasive melanoma (6%). Conclusion In this large case–control study from across Europe the expected associations were confirmed for known risk factors. Some possible new risk factors, including cardiac and diuretic drugs, were identified, creating a new field for further investigation in future studies.
722. SeV RNA Replicon Vector: An Efficient Cytoplasmic Expression System Derived from Sendai Virus Self-Replicating Ribonucleoprotein Complexes
Authors: Akihiro Iida, Mamoru Hasegawa
Journal: Molecular Therapy (2004)

Sendai virus (SeV) is an enveloped virus with a nonsegmented negative strand RNA belonging to Paramyxoviridae family. We have previously shown that recombinant SeV as well as its modified non-transmissible variants can efficiently transfer and express foreign genes for a broad range of mammalian cells and tissues in vitro and in vivo and are suitable for use in gene therapy. SeV has two envelope glycoproteins HN and F, which mediate the virus attachment to and penetration into target cells, respectively. These envelope glycoproteins are not only important factors for viral tropism but also major determinants of immunogenicity in infected animals. Here we report the development of a novel SeV RNA replicon vector system that takes advantage of SeV self-replicating ribonucleoprotein complexes (RNP). In the vector system, RNP itself is non-infectious and can be infectious by the addition of lipofection reagents. In this system, nuclear entry of SeV RNA genome which forms an RNP complex with SeV NP, P and L proteins is not required and high expression of transgene is expected in transduced cells by self-replication of RNP in the cytoplasm. In addition, no effect of transduction of transgene in the presence of neutral antibody against SeV is expected. As the source of RNP, non-infectious virus-like particles (VLP) were recovered by infecting F-defective SeV vector into LLC-MK2 cells and harvesting VLP from the supernatants of the infected cells. To qualitatively and quantitatively compare this new vector system with conventional SeV vector or plasmid DNA, we introduced β-galactosidase, luciferase or enhanced green fluorescent protein (EGFP) reporter gene into the F-defective SeV genome, and recovered VLP from cloned cDNAs. The SeV RNA replicon vector mixed with lipofection reagents efficiently transferred foreign genes to several mammalian cell lines in vitro, and dose-dependently expressed luciferase or EGFP genes in tranduced cells. The expression level of SeV RNA replicon vector was comparable to that of SeV F-defective vector and remarkably higher than plasmid DNA-liposome complexes. Transduction of a foreign gene by SeV RNA replicon vector was not inhibited by the addition of an anti-SeV-HN antibody, although transduction by conventional SeV vector was completely inhibited. Therefore, the SeV RNA replicon vector system is useful for cytoplasmic expression of foreign genes in vitro and may be of help to its application to human gene therapy such as repeated administration and targeting of the vector.